Regencell Bioscience Holdings Ltd

Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. It seeks for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder and autism spectrum disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Earnings data Q1 2024

Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. It seeks the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder and autism spectrum disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

HONG KONG--(BUSINESS WIRE)---- $RGC #ADHD--Regencell Bioscience Holdings Limited (Nasdaq: RGC) (“Regencell”) today announced its interim results from its second efficacy trial. Regencell conducted its second efficacy trial using standardized Traditional Chinese Medicine (“TCM”) formulae. “Our aim is to save and improve lives by making our standardized TCM formulae widely available to ADHD and ASD patients around the world. It is known that there is a significant economic impact and increased parental burden t

Regencell Bioscience's Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial

Regencell Bioscience is an early-stage bioscience company focused on the research, development, and commercialization of Traditional Chinese Medicine. Regencell Chairman and CEO, Yat-Gai Au recently purchased more than $5.9 million in RGC shares.

Slow And Steady Wins The Race With Regencell Bioscience

Albertsons Companies

Clearway Energy

HealthStream

Coca-Cola

Altria

National HealthCare

NRG Energy

PG&E

Is the United States heading toward a recession? This has been the looming question on the minds of Americans since inflation topped at 8.5% in March, matched with other indicators such as rising interest rates and the bond market's inverted yield curve.

Sector Rotation And 9 Stocks To Watch During A Recession

HONG KONG--(BUSINESS WIRE)---- $RGC #ADHD--Regencell Bioscience Holdings Limited (NASDAQ: RGC): Results of EARTH efficacy trial   EARTH Efficacy Trials Period of trial 30 January 2022 – 31 March 2022 (EARTH-B Trial) 1 October 2021 – 31 January 2022 (EARTH-A Trial) 1 October 2021 – 31 March 2022 (EARTH-A and EARTH-B Trials, combined) Number of patients 51 37 88 Complete symptoms elimination in 6 days (% of patients) 94.1 97.3 95.5 Elimination of one or more symptoms after 1 full dose of RGC-COV19TM (% of patie

Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period

HONG KONG--(BUSINESS WIRE)---- $RGC #ADHD--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focusing on the research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced that Yat-Gai Au, the Company's Chairman and CEO, made purchases of ordinary shares in Regencell (“Ordinary Shares

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

LOS ANGELES, CA / ACCESSWIRE / March 1, 2022 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with the team from Regencell Bioscience Holdings Limited (NASDAQ:RGC), including: Jay Lee, CEO of Regencell Bioscience Asia Limited, and Paul Niewiadomski, Independent Director. Regencell is an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, according to the company's website (see here: www.regencellbioscience.com).

Regencell Describes Their Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results in New Video Interview on SNN Network

Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced the results from the EARTH efficacy trial of its COVID-19 candidate. RGC-COV19 (Regencell Bioscience (RGCA-CV01) liquid formulation) is an oral TCM candidate.

Regencell Bioscience's COVID-19 Candidate Shows Encouraging Action On Mild To Moderate Symptoms

HONG KONG--(BUSINESS WIRE)---- $RGC #ADHD--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”) today announced the results from an analysis of a total of 37 individuals enrolled in its Evaluation and Assessment of RGC-COV19TM TCM through a Holistic approach (“EARTH”) efficacy trial conducted by Regencell Bioscience Asia Limited (“Regencell Asia”) of its novel COVID-19 oral TCM candidate RGC-COV19TM (Regencell Bioscience (RGCA-CV01) liquid formulation). The results have yet to be

Regencell Bioscience's Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced the appointment of Dr. William Wing-Yan Lo, JP to its Board of Directors, effective immediately, to strengthen its Board of Director and fill the v

Regencell Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced that Yat-Gai Au, the Company's Chairman & CEO, made Ordinary Share purchases of Regencell (“Ordinary Shares”) totaling $1,125,807. As per the S

Regencell Bioscience Holdings Limited Announces Over $1 Million Ordinary Share Purchase by CEO

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced that the ordinary shares of the Company will be added to the MSCI World Micro Cap Index on November 30, 2021 after the close of market (effective D

Regencell Bioscience Holdings Limited Included in the MSCI World Micro Cap Index

Regencell Bioscience Holdings Ltd's (NASDAQ: RGC) subsidiary in Hong Kong has entered into a joint venture agreement with Honor Epic Enterprises Limited to offer COVID-19 related treatments. The joint venture will cater to patients in ASEAN countries, India, Japan, Australia, and New Zealand.

Regencell Bioscience Stock Jumps On Formation Of COVID-19 Treatment Focused Joint Venture

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), today announced that Regencell Bioscience Limited (“Regencell HK”), the Company's wholly-owned subsidiary in Hong Kong, has entered into a joint venture agreement with Honor Epic Enterprises Limited (“Honor Epic”). The joint venture (“JV”) is expected to offer COVID-19 (“COVID”) related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand. As COVID vaccin

Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment

The stock price of Regencell Bioscience Holdings Ltd (NASDAQ: RGC) increased by over 40% pre-market. This is why it happened.

RGC Stock: Over 40% Pre-Market Details

The shares of Regencell Bioscience Holdings Ltd (NASDAQ: RGC) increased 204.13% in the previous trading session on August 20. This is why it happened.

Regencell Bioscience Shares Increased 204.13%: Why It Happened

Will RGC Stock Crash Or Go Higher After Today? The post Is RGC Stock Rallying On Mistaken Identity?

Is RGC Stock Rallying On Mistaken Identity?

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine ("TCM") for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder ("ADHD") and Autism Spectrum Disorder ("ASD"), today announced that the underwriter of its initial public offering (the “Offering”) had

Regencell Bioscience Holdings Limited Announces Partial Exercise of Underwriter's Over-Allotment Option

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company today released a letter from Yat-Gai Au, Founder and Chief Executive Officer of the Company. Dear Shareholders: As CEO of Regencell, I am pleased to take this opportunity to discuss the significant milestones we achieved thus far in 2021, update our shareholders on our business plan for the remainder of the year and discuss our goals for 2022 and beyo

Regencell Bioscience Holdings Limited Releases CEO Letter to Shareholders

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ:RGC) (“Regencell” or the “Company”), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”), today announced the closing of its initial public offering (the “Offering”) of 2,300,000

Regencell Bioscience Holdings Limited Announces Closing of Initial Public Offering

Blend Labs

Bridge Investment Group Holdings

Erasca Inc

Imago Biosciences

Stevanato Group SpA

The group is diverse—a fintech, three biotechs, a real-estate investment manager, a bioscience company, and a pharmaceutical glassmaker.

7 Companies Begin Trading. Here's How They're Doing.

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ:RGC) (“Regencell” or the “Company”), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”), today announced the pricing of its initial public offering (“Offering”) of 2,300,000 ordi

News for Regencell Bioscience Holdings Ltd Stock (RGC)